# JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal Carcinoma

> **NCT07690787** · PHASE2 · RECRUITING · sponsor: **Chinese University of Hong Kong** · enrollment: 49 (estimated)

## Conditions studied

- Recurrent/ Metastatic NPC

## Interventions

- **DRUG:** JS207
- **DRUG:** Paclitaxel
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT07690787
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-29
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2026-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07690787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07690787, "JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07690787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*